ABCB1 and cancer: Our data revealed that furmonertinib effectively resensitized NCI-ADR-RES (Figure 1A–C) and KB-V1 (Figure 1D–F) cancer cells, as well as MDR19-HEK293 cells (Figure 1G–I), to ABCB1 substrates colchicine, vincristine, and paclitaxel in a concentration-dependent manner.